Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - ANANDA Scientific

Drug Profile

Cannabidiol - ANANDA Scientific

Alternative Names: A-1002-N5S; Cannabidiol - ANANDA Scientific; Liquid Structure™ Cannabidiol; Liquid Structure™ CBD; Nantheia™; Nantheia™ ATL5

Latest Information Update: 28 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ISA Scientific
  • Developer ANANDA Scientific; Ben Gurion University; David Geffen School of Medicine at UCLA; NYU Grossman School of Medicine
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Opioid-related disorders; Post-traumatic stress disorders; Social phobia
  • Clinical Phase Unknown Neuropathic pain
  • Research Psoriasis
  • No development reported COVID 2019 infections; Diabetes mellitus

Most Recent Events

  • 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (PO)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Israel (PO)
  • 23 Dec 2022 Phase-II clinical trials in Social phobia in USA (PO) (NCT05571592)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top